Skip to content
Surrogate endpoints with Huseyin Naci episode artwork

Nov 11, 2022 47 min

Surrogate endpoints with Huseyin Naci

from BMJ talk medicine Hosted by BMJ Group

This week, we’re joined by Huseyin Naci to discuss the recent press release from Eisai and Biogen announcing the Phase III trial results for lecanemab for use in Alzheimer’s disease, and the FDA’s decision to accept the drug onto its accelerated approval pathway. We talk about the pros and cons of using surrogate endpoints to predict clinical outcomes. How can we strike a better balance in clinical trials between generating high-quality and trustworthy evidence, and the urgent needs of patients with life-limiting conditions and very few available treatment options? Our guest: Huseyin Naci is an associate professor of Health Policy at the London School of Economics and Political Science (LSE). He is also an advisor to the Analysis section of The BMJ.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Surrogate endpoints with Huseyin Naci

0:00 47:12

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BMJ talk medicine?

This episode is 47 minutes long.

When was this BMJ talk medicine episode published?

This episode was published on November 11, 2022.

Can I download this BMJ talk medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.